Our study has demonstrated that carbon polymer array electronic nose breath profiling allows accurate discrimination between patients with MM, healthy control subjects and subjects with benign asbestos-related diseases
2011
Key concepts
Scholarcy highlights
- Malignant mesothelioma is a rare tumour which is difficult to diagnose in its early stages
- FEV1, FVC and FEV1/FVC ratio were significantly reduced in subjects with benign asbestos-related diseases compared with healthy control subjects
- Our study has demonstrated that carbon polymer array electronic nose breath profiling allows accurate discrimination between patients with MM, healthy control subjects and subjects with benign ARDs
- This is the second published report of the use of electronic nose breath profiling in MM and substantiates the promise of this technique as a simple, easy way for detecting malignancy which has previously been reported for lung cancer
- A study by DRAGONIERI et al published very recently, while our paper was under review, reports high levels of discrimination between patients with MM and those with long-term asbestos exposure using an electronic nose system, with results almost identical to those of our study
- Smell prints from 10 new MM patients were distinguished from control subjects with an accuracy of 95%
- This work exemplifies the novel use of this technology for differentiating individuals with asbestos exposure and benign conditions from those with malignant disease
- The carbon polymer array electronic nose distinguished accurately between benign and malignant asbestos-related diseases, implying that the breath profile of volatile organic compounds in MM is very different
Need more features? Save interactive summary cards to your Scholarcy Library.